Skip to main content

Cerebral Amyloid Angiopathy cAPPricorn-1

Status: Open to Enrollment
Email Us To Enroll

Study Details

View study details on clinicaltrials.gov.

Locations

  • San Francisco
  • Sacramento

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.

Armen Moughamian
Armen Moughamian
Principal investigator
View Profile
Shawn Kile
Shawn Kile
Principal investigator
View Profile

Co-investigators

Travis J Urban, Chen Zhao

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?